LARGO, Fla., January 28, 2026 -(BUSINESS WIRE)- CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2025.
Fourth Quarter 2025 Highlights
- Sales of $373.2 million increased 7.9% year-over-year as reported and 7.1% in constant currency.
- Domestic revenue increased 1.4% year-over-year.
- International revenue increased 17.0% year-over-year as reported and 15.4% in constant currency.
- Diluted net earnings per share (GAAP) were $0.54, compared to diluted net earnings per share (GAAP) of $1.08 in the fourth quarter of 2024.
- Adjusted diluted net earnings per share(1) were $1.43, compared to adjusted diluted net earnings per share of $1.34 in the fourth quarter of 2024.
Full-Year 2025 Highlights
- Sales of $1,374.7 million increased 5.2% year-over-year as reported and 5.1% in constant currency.
- Domestic revenue increased 3.5% year-over-year.
- International revenue increased 7.4% year-over-year as reported and 7.1% in constant currency.
- Diluted net earnings per share (GAAP) were $1.51, compared to diluted net earnings per share (GAAP) of $4.25 in 2024.
- Adjusted diluted net earnings per share(1) were $4.59, compared to adjusted diluted net earnings per share of $4.17 in 2024.
“Our fourth quarter results reflect steady execution across the business as well as progress on our operational initiatives,” said Patrick J. Beyer, CONMED’s President and Chief Executive Officer. “As we begin 2026 with a sharpened strategic focus, we remain disciplined in our operating approach and confident in the long‑term potential of our key growth drivers in minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair.”
2026 Outlook
The Company expects full-year 2026 reported revenue between $1.345 billion and $1.375 billion. This represents year over year organic constant currency growth of approximately 4.5% to 6% over 2025 revenue when excluding sales of gastroenterology products from both years, and approximately 0 to 50 basis points of currency tailwind.
The Company expects full-year 2026 adjusted diluted net earnings per share(2) in the range of $4.30 to $4.45. This includes a currency tailwind of approximately $0.10.
Supplemental Financial Disclosures
(1) A reconciliation of reported diluted net earnings per share to adjusted diluted net earnings per share, a non-GAAP financial measure, appears below.
(2) Information reconciling forward-looking adjusted diluted net earnings per share to the comparable GAAP financial measures is unavailable to the company without unreasonable effort, as discussed below.
Conference Call
The Company’s management will host a conference call today at 4:30 p.m. ET to discuss its fourth quarter and full-year 2025 results.
To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode.
This conference call will also be webcast and can be accessed from the “Investors” section of CONMED’s website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
